Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Critical Mineral Executive Order Issued by President Donald Trump (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Coherus BioSciences Inc CHRS

Healthcare Biotechnology
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:CHRS)

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire March 10, 2025

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

GlobeNewswire March 3, 2025

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

GlobeNewswire February 24, 2025

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

GlobeNewswire January 22, 2025

Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 8, 2025

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

GlobeNewswire December 18, 2024

Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd.

GlobeNewswire December 3, 2024

Coherus Management to Participate in the 2024 Citi Global Healthcare Conference

GlobeNewswire November 27, 2024

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire November 6, 2024
View More News ››

Opinion & Analysis (NDAQ:CHRS)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:CHRS)

Anyone heard anything about CHRS presentation yesterday?

CHRS presented yesterday at J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 5:15 p.m. Pacific Time. The presentation...
Humanist - January 14, 2025

anyone deals with cibc experienced tech difficulties TDY?

PLS LET ME KNOW .. THX 
Humanist - December 9, 2024

Coherus Divesting UDENYCA Franchise to Intas Pharmaceuticals

News; $CHRS Coherus Divesting UDENYCA Franchise to Intas Pharmaceuticals for up to $558M2024-12-03 08:20:04 ET DENVER, Colo., Dec 03...
whytestocks - December 3, 2024

CHRS agrees to divest Udenyca for $558 mlns to INTAS

Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million to Intas Pharmaceuticals Ltd. Coherus BioSciences...
Humanist - December 3, 2024

CHRS REPORTS 3RD QTR EARNINGS & PROVIDE BUS UPDATES TDY AMC

Coherus BioSciences Reports Third Quarter 2024 Financial Results and Provides Business Update Coherus BioSciences, Inc. Coherus...
Humanist - November 6, 2024

CHRS was mentioned tdy MAR. 4th by MARC CUBAN on CNBC

CHRS MENTIONED AS HAVING  BIOSIMILAAR DRUGS LIKE HUMIRA THATS WAY CHEAPER ETC..   LINK BELOW FOR THE INTERVIEW ... GOOD...
Humanist - March 4, 2024
View more Bullboard ››

EnviroGold Global Limited.

EnviroGold Global Limited.

EnviroGold Global Limited is a Canadian headquartered clean technology company with a global vision and a strategic focus ...
View More »